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Editorial on the Research Topic
Harnessing the Participation of Dendritic Cells in Immunity and Tolerance
Dendritic cells (DCs) are cells of the innate immune system directly associated with the instruction
and regulation of the adaptive immune response, thus bridging the innate and adaptive immune
systems (1). DCs are the main antigen presenting cells (APCs), specialized in naive T cell priming
into effector T cells. DCs recognize, internalize, process, and present antigens complexed to class I
and II major histocompatibility complex molecules (MHCs), providing the three signals necessary
for efficient T cell activation (2). Thus, DCs are essential for the induction of immune responses
mediated by CD4+ and CD8+ T cells and, directly or indirectly, by B cells (3, 4).
However, DCs are not a homogeneous cell line, on the contrary, there are several subtypes that
can be classified according to membrane markers and/or function. Basically, they can be classified
into plasmacytoid and classical/conventional DCs (5, 6). Plasmacytoid DCs (pDCs) are specialized
in the expression of type I interferons (IFN), responding quickly and efficiently to viral infections
(7). Recent advances in the knowledge of their ontogeny, both in humans and in mice, are carefully
reviewed by Musumeci et al., while Ali et al. review in detail the role of type I IFN production
by these cells, but also by other cell types. Recent data indicate that several other cell types play
a prominent role in the production of type I IFN, depending on the pathogen causing infection.
Classical DCs (cDCs), on the other hand, are mainly associated with antigen presentation and T
cell instruction. Most often, cDCs are subdivided into different subtypes based on the expression
of various surface markers. However, a new classification according to their ontogeny has been
proposed, as the functional identity of these cells is determined by their differentiation process
(6, 8). A detailed review of the two main subtypes of cDCs (cDC1s and cDC2s), as well as their
markers and location in different tissues, is presented by Backer et al. which, in addition, explore
in great detail the origin, location, and role of splenic CD8α+Langerin+ cDC1s in the context of
systemic infections and immunotherapy. Complementing the previous review, Prendergast et al.
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report that CD8α+Langerin+ cDC1s play an essential role in
sepsis control (in a mouse model using BCG administered iv) as
they activate CD8+ T lymphocytes and IL-12 production, which
appear to be essential for the initial control of systemic bacterial
infections. The role of cDC1s in anti-tumor immunity has not
been fully clarified and Cancel et al. explore the latest literature
on the subject providing evidence, mainly in animal models,
that cDC1s have an important role in priming and/or sustaining
the activation of both, T lymphocytes and NK cells. Human
studies also point to a strong association between typical cDC1s
signatures and a better prognosis for some types of tumors.
The role of cDC1s in cancer, as well as the cross-talk between
these cells and other DC subtypes and cell types, is discussed
in detail by Noubade et al. who argue that understanding these
interactions is important for the design of more effective DC-
based cancer immunotherapies.
In this topic, the role of other cDC subtypes in different
inflammatory, infectious diseases, and cancer was also explored.
Tiburcio et al. analyze the interaction between DCs and
Leishmania parasites, trying to elucidate the role of DCs in
establishing the immune response in leishmaniasis and how this
parasite subverts this response to establish itself. Furthermore,
Nico et al. showed that a vaccine using Leishmania (L.) donovani
antigens was able to prevent the dysfunctional migration of
DCs seen in this animal model, and induce a protective
response against this parasite. In the case of bacterial diseases,
Richardson et al. demonstrated that dendritic cells derived
from human monocytes (moDCs) are modulated by peptides
derived from Staphylococcus aureus becoming more tolerogenic
and consequently inducing regulatory T lymphocytes. The use
of these peptides in vaccine strategies against autoimmune
diseases appears very promising. Another molecule, derived
from gram-negative bacteria, that has also been explored as an
adjuvant in vaccination protocols, is flagellin. Flores-Langarica
et al. demonstrate that lamina propria CD103+CD11b+ cDC2s
respond to flagellin and are essential for the induction of T and
B lymphocytes in the mucosa, especially inducing a Th2 type
response. The effect of flagellin was further explored by Dos Reis
et al. when moDCs from HIV-infected patients were treated with
this compound. The treatment with flagellin suggested that this
molecule was able to activate the inflammasome NAIP/NLRC4
and thereby promote the activation of moDCs derived from
HIV+ patients. Still in the context of HIV infection, Schonfeld
et al. found that the infection of moDCs with the sexually
transmitted bacteria Chlamydia trachomatis followed by HIV
infection was able to increase viral infection and to reduce the
activation of cytotoxic T lymphocytes.
The role of different DC subtypes has been reviewed in
the context of autoimmune diseases and pulmonary arterial
hypertension (van Uden et al.). Although several DC subtypes
were found to be involved, the exact functional role of each
one, or of their interactions, in the development of these
pathologies needs to be further defined. In fact, the crosstalk
between different DC subtypes or with other cell types is
extremely important, both in the steady state and in the
context of inflammation. Grabowska et al. dedicate a detailed
review on the interaction between CD169+ macrophages and
DCs in the contexts of immunity and tolerance, presenting
evidence that suggests that these cells greatly interact with each
other, and that the cytokines produced by macrophages have
an important impact on the activation of adaptive responses
initiated by DCs against different pathogens. On the other
hand, Wagner et al. evaluate the role of pDCs and 6-sulfo
LacNAc-expressing monocytes (slanMo) in rectal cancer after
neoadjuvant radiochemotherapy, and demonstrate that the
benefits of this therapy in this particular cancer type may be
related to increased infiltration of activated pDCs expressing
IFNα and cytotoxic CD8+ T lymphocytes. Complementing these
results, Ahmad et al. not only revise the role of slanMo in cancer,
but also in other pathologies.
Most of the studies carried out to better characterize DCs
and their functions and interactions have exploited either
animal models or adult human samples. However, in recent
years, different groups were dedicated to study the functional
differences between the DC subtypes found in neonates and
in adult individuals. Papaioannou et al. review such efforts
and speculate on strategies that could be applied to promote
neonatal immunity.
The capacity of DCs and other APCs in sensing the
environment in which they are situated allows them to respond,
or not, to different external stimuli. The ability of DCs and other
APCs to respond to different sugars has been highlighted for
the induction of immunity as well as tolerance. Lubbers et al.
present a detailed review of how signaling through receptors
that bind sialic acid is important in inducing immune tolerance,
and how this knowledge could be utilized to develop strategies
to treat autoimmune diseases or allergies. Another pathway
capable of suppressing DC functions is that of adenosine (Ado),
a metabolite of extracellular ATP (which acts as a danger signal
in the context of inflammation). Silva-Vilches et al. present a
careful review of how extracellular Ado suppresses the functions
of DCs previously activated by the presence of extracellular ATP.
Another important contribution was made by Han et al. who
suggested that deficiency in Fas signaling in DCs increases allergy
by inducing pulmonary inflammation mediated by the activation
of a potent Th2 response. Other articles have explored not the
signaling pathways, but rather the role of different transcription
factors in DC activity. Sondergaard et al. and Tel-Karthaus et
al. evaluate the role of DC-SCRIPT and Nur77 transcription
factors, respectively, in human moDCs, demonstrating that both
control the activation and presentation capacity of these cells,
thereby modulating the activation of immune responses. The
transcription factor Zeb1, on the other hand, seems to mediate
the production of IL-6, IL-10, and IL-12 by cDC1, thus inducing
a pro-inflammatory response (Smita et al.).
The success of DCs in antigen presentation and T cell priming
can be partly explained by their remarkable ability to efficiently
present internalized exogenous antigens in MHC I molecules.
This phenomenon is known as cross-presentation. Through this
process, DCs (especially the cDC1 subtype) are able to activate
CD8+ T lymphocytes that play an important role during the
course of the immune response, especially in viral infections
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and tumors. Three reviews discuss our current knowledge
on the pathways that lead to efficient cross-presentation by
DCs, from the acquisition of the exogenous antigen to its
processing and peptide loading in the MHC I. Embgenbroich
and Burgdorf discuss the two main cross-presentation pathways
(the endosome-to-cytosol and the vacuolar pathways), while
Gros and Amigorena emphasize what is currently known about
the mechanisms for antigen export to the cytosol. Finally,
Montealegre and van Endert debate in great detail the differences
in the recycling pathways between DCs and non-antigen
presenting cells. Despite some controversies in the field, these
authors elegantly present an overview of the state-of-the-art of
this very important phenomenon in DC biology.
Their incredible ability to modulate immune responses
transforms DCs into ideal targets for manipulation. Once it
was demonstrated that functional DCs could be obtained from
peripheral blood monocytes (moDCs) (9), the next logical step
was to produce these cells, load them with target antigens, induce
maturation and administer them as vaccines. The first attempts
to use autologous DCs loaded with antigens were made in
patients with B-cell lymphomas more than two decades ago (10).
Patente et al. review the clinical application of this technology,
especially in cancer patients. In complement Huber et al., not
only elaborate in detail the results obtained with the use of
autologous moDCs in the treatment of cancer, but also present
the potential use of the other subtypes of cDCs in this setting.
On the other hand, da Silva et al. review the progress obtained
with the use of moDCs for the treatment of HIV infection.
Despite the various advances in the use of autologous moDCs
as vaccines, the fact that these preparations are laborious, time-
consuming and extremely expensive have led to research aimed
at directing antigens directly to the different DC subtypes in
vivo. Several strategies were then devised and promising results
have been obtained in animal models. Kroczek et al. describe the
use of the chemokine (C motif) ligand 1 (XCL1) to target the
antigen to its receptor (XCR1) in cDC1s, while Koerner et al.
review the use of poly (D, L-lactide-co-glycolide) microspheres
(PLGAMS) in directing antigens to DCs. Antigen targeting using
monoclonal antibodies (mAbs) against DC surface receptors
fused to proteins of interest has also been studied as a promising
way to deliver the antigen of interest to these cells. Apostolico
et al. and Antonio-Herrera et al. explore the use of different
adjuvants in combination with the administration of chimeric
mAbs to improve the induced immune response. Differently,
Zaneti et al. direct the antigen of interest through a DNA vaccine
that encodes a single-chain Fv antibody designed to be secreted
and direct the fused protein to cDC1s. In all cases, activation of
the immune system was observed.
The use of animal models to study DCs ontogeny or the
effect of ablation of a specific subtype on the development of the
immune response can be very useful. In this context, Iwabuchi
et al. created a model of humanized mice that allowed them to
study the effect of fms-related tyrosine kinase 3 ligand (Flt3-
L) and granulocyte-macrophage colony-stimulating factor (GM-
CSF) cytokines on the development of human DC subtypes,
Moreover, Mattiuz et al. were able to generate mouse strains
capable of specifically depleting cDC1s. Further studies using
these models will be important to determine cDC1 function in
different settings.
In conclusion, this topic presents articles that contribute to a
broader understanding not only of DC biology, but also of the
processes involved in the many functions that these cells play
during steady-state or infections/inflammation.
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